Compound for specifically binding to amyloid β-protein
US10239895B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jun 18, 2018 |
| Grant date | Mar 26, 2019 |
| Priority date | — |
| Expiry date | Jun 18, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/4709
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a compound for specifically binding to amyloid β-protein. The compound has thereon a nuclide with a large thermal neutron capture cross section and the compound is capable of specifically binding to the amyloid β-protein. The property of the compound allows it to be used in conjunction with a neutron capture therapy device to eliminate amyloid β-protein. Similarly, when the compound is labelled with radioactive element 11C, the compound can also be used in conjunction with PET/CT for determining the part of the brain where amyloid β-protein is deposited, for diagnosing Alzheimer's disease. Also disclosed is a preparation process for the compound. The beneficial effect of the present disclosure is to make the therapy and diagnosis of Alzheimer's disease more targeted by providing the compound for specifically binding to amyloid β-protein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.